Dermata Therapeutics- Warrants (13/08/2026) Current Cash

As of the most recent data (June 2026), DRMAW shows a current cash of $4.4M. That compares with $6.5M in the prior-year period — down 31.9% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, DRMAW's current cash is now $4.4M (was $6.5M) — a 31.9% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Dermata Therapeutics- Warrants (13/08/2026) is outperforming or lagging.

Tracking DRMAW's current cash over time shows whether Dermata Therapeutics- Warrants (13/08/2026) is scaling, shrinking, or reshaping that part of the business. The current reading is $4.4M That compares with $6.5M in the prior-year period — down 31.9% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this current cash page, Stockcircle has Dermata Therapeutics- Warrants (13/08/2026)'s full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect current cash (currently $4.4M) with ownership activity and broader fundamentals.

Dermata Therapeutics- Warrants (13/08/2026)'s current cash is $4.4M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.